The ONS Podcast

27:46

Episode 436: Oncologic Emergencies 101:...

The ONS Podcast ·

2026/10/09

"The most important thing related to hypersensitivity reactions is that there is often a potential for rapid progression, and that's what makes these reactions an oncologic emergency. The patients may have symptoms that are mild, and that quickly can progress to respiratory compromise, hypertension, cardiovascular issues, or anaphylaxis. Early recognition is so important, so we don't want to wait for our patient to become hypotensive or significantly hypoxic before we identify that they're having

en

35:34

Episode 435: An Overview of Hodgkin Lymphoma for...

The ONS Podcast ·

2026/10/02

"The accumulation of these malignant and reactive cells, that's what causes the lymph nodes to get big. That's why they grow. And that's why the classic presentation is persistent, painless, enlarged lymph nodes. So when we think of the pathophysiology of Hodgkin lymphoma, there are really two processes contributing to the presentation: One is the physical effects of enlarging lymph nodes or the involved organs. The second is the systemic inflammatory response generated by it and its surrounding

en

34:23

Episode 434: Oncology–Psychiatric RN Collaboration to...

The ONS Podcast ·

2026/09/25

"Nurses are the front line. Oncology nurses see their patients almost all day. If you're noticing that anxiety is causing significant distress or anxiety is disrupting a patient's ability to concentrate during medical conversations or decision-making—anytime you're seeing significant distress or disruption to functioning, that's a pretty good indicator that referral to a psychiatric nurse and psychiatric care could be very helpful for that patient," Amber Altidor, DNP, APRN-FPA, PMHNP-BC, assistant

en

33:46

Episode 433: Cancer Treatments for Noncancer...

The ONS Podcast ·

2026/09/18

"Unlike our cancer indications where we use these medications often to activate the immune system to target cancerous cells, in noncancer indications, the goal is really to either suppress an overactive immune or inflammatory cells or modulate the immune system. Immune modulation by use of chemotherapy and immunotherapy can help reduce abnormal inflammation, decrease autoantibody production, and also can alter T-cell and B-cell activity," ONS member Kelsey Miller, MSN, RN, AGCNS-BC, OCN®, clinical

en

31:40

Episode 432: Long-Term Chronic Lymphocytic Leukemia...

The ONS Podcast ·

2026/09/11

"It's a chronic disease. It never goes away for some people, and so therefore it has these periods of remission where it's really quiet and well controlled. Then there can be periods of flares where you're actively engaged in treatment or it's impacting other pieces. There's this feeling patients have of, 'When am I going to have that flare?' You know, this anticipatory anxiety of, 'When are things going to be done differently?' or 'When do I need to change?'" ONS member Caitlin Murphy, DNP, APRN,

en

19:14

Episode 431: Oncologic Emergencies 101: Urinary...

The ONS Podcast ·

2026/09/04

"Think about all the important things our kidneys do for the body. Those things are compromised. If we have excess buildup of toxins and waste in the body, you're having problems with fluid reabsorption. Then you have also problems with electrolytes not being balanced. Then in turn, you have ongoing shutdown of systems. So the cardiopulmonary system gets compromise. Your circulatory system then gets compromised. And then all the things in the body that depend upon ongoing circulatory flow are then

en

34:08

Episode 430: Leadership Unlocked: Is It Your Time to...

The ONS Podcast ·

2026/08/28

"If you are considering board service, I would say take the leap. Start with your local chapter. It will give you some valuable skills that will help prepare you when you are applying for your national level. And I always say, if you want to do it, just do it because what's the worst that can happen? They can say no, but that doesn't mean that you will never serve on a board. I always tell people delayed is not denied," Cassandra Green, DNP, RN, OCN®, ONS member and past president of the Oncology

en

36:15

Episode 429: Radiation Site-Specific Side Effects:...

The ONS Podcast ·

2026/08/21

"They're really worried that radiation is going to be painful. So they come in for that first day of treatment very anxious. With our patients with brain cancer, we're using the masks on the table, and those masks are very tight and hold their heads very, very still. So they'll be very worried about being claustrophobic. We may start out the first day or two with a little bit of [lorazepam]. And they'll come to me and they'll say, 'This really hasn't been as bad as I thought it was going to be,'"

en

49:10

Episode 428: Chronic Lymphocytic Leukemia Treatment...

The ONS Podcast ·

2026/08/14

"Measurable residual disease is where I think the terminology fits best in that, it is intended to measure the amount of cancer cells that are present in the blood or bone marrow at the time the sample was collected. We can identify one cancer cell in a million. Where that can be really valuable is when we start to think about the duration of treatments and the response to some of our treatments," ONS member Caitilin Murphy, DNP, APRN, FNP-BC, AOCNP®, chief nurse practitioner at Dana-Farber Cancer

en

29:29

Episode 427: Pharmacology 101: Resistance Pathways

The ONS Podcast ·

2026/08/07

"A good way of thinking about this is this is the survival of the fittest clone. There could be a portion of a cancer that naturally has some resistance or ability to survive a particular drug. And over time, as the other cells around it are dying off, that particular clone is able to replicate and continue to survive in the face of that drug therapy and eventually take over as being the fittest clone. At that point, we're often seeing disease progression," Danielle Roman, PharmD, BCOP, manager of

en

42:23

Episode 426: Tools to Support Patients and Nurses...

The ONS Podcast ·

2026/07/31

"When people with PTSD [post-traumatic stress disorder] get quite avoidant—and that can be expressed in so many different ways—the implications can be really profound. I think an important invitation to oncologists and oncology nurses and primary care providers who care for people battling cancer is let's explore what's underneath these avoidant behaviors. Is it a very practical thing? Or is it that underneath this avoidant behavior is really profound fear?" James C. Jackson, PsyD, research

en

29:38

Episode 425: How AI Can Help Healthcare...

The ONS Podcast ·

2026/07/24

"In oncology specifically, where care is complex, artificial intelligence (AI) can really synthesize large volumes of clinical information, flag risks such as treatment complications, and support adherence to evidence-based pathways. For nurses specifically, this enables them more time for direct patient care, clinical judgment, and care coordination, and really practice to the top of their license while reducing repetitive time and administrative tasks," Jenn Frith, DNP, RN, OCN®, NE-BC, associate

en

47:32

Episode 424: Radiation Site-Specific Side Effects:...

The ONS Podcast ·

2026/07/17

"Think about what organs lie in the radiation field, and anything that lies in that radiation field is likely going to have some potential temporary—hopefully temporary—side effects. If you think about the pelvis, the things that live in there are the bladder, urethra, some bowel, rectum, reproductive organs, skin, some lymph nodes. And so, all of those things could potentially have associated side effects," ONS member Kayla Kafka-Peterson, BSN, RN, ROCN™, nurse navigator and leader in the

en

30:10

Episode 423: Pharmacology 101: Interaction Pathways

The ONS Podcast ·

2026/07/10

"When we think of drug interactions, specifically, the National Cancer Institute actually defines this as a change in the way a drug acts in the body when taken with certain other drugs, herbals, or foods or when taken with certain medical conditions. Drug interactions may cause the drug to either be more or less effective or cause effects on the body that are not expected," Carissa Ganihong, PharmD, BCOP, oncology and bone marrow transplantation clinical pharmacist at Hackensack University

en

47:30

Episode 422: An Overview of Chronic Lymphocytic...

The ONS Podcast ·

2026/07/03

"What I appreciate about our patients with chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia is the consideration that they receive a cancer diagnosis, and the best thing for them to do is actually nothing. There is a large population of patients that we don't recommend any type of treatment. We recommend that they establish care with an oncologist and that they have a relationship with those care teams," ONS member Caitilin Murphy, DNP, APRN, FNP-BC, AOCNP®, chief nurse practitioner

en

41:19

Episode 421: Medical Trauma in Oncology

The ONS Podcast ·

2026/06/26

"There are a huge array of medical dynamics that people endure, and when they leave a lasting impact, a word that we don't use widely enough is the word 'trauma.' There's an entire category of phenomena in the medical arena that are, in fact, traumatic. One way we know that these experiences are traumatic is that we know that huge portions of people who experience things like cancer do indeed develop problems like [post-traumatic stress disorder]," James C. Jackson, PsyD, research professor at

en

43:04

Episode 420: Long-Term Myelodysplastic Syndrome...

The ONS Podcast ·

2026/06/19

"We typically think of the disease progressing for our higher-risk patients because many of them already start with increased blasts or a lot of dysplasia. And they have these chromosomal variants that make them prone to evolving into acute myeloid leukemia (AML). With them, we can anticipate that they are going to progress to AML. And that's what we're trying to prevent. It's kind of like a biologic evolution and not a switch," ONS member Sara Tinsley-Vance, PhD, APRN, AOCN®, nurse practitioner and

en

44:26

Episode 419: Pharmacology 101: Immunomodulators

The ONS Podcast ·

2026/06/12

"Until immunomodulators, patients [with myeloma] did not have a great overall survival rate. But when we introduced lenalidomide, we started seeing our patients have life expectancies between five and seven years—which was unheard of prior to these immunomodulators going forward. I think it's promising and allows patients to have quality of life versus therapy of life," ONS member Daniel Verina, DNP, RN, ACNP-BC, nurse practitioner for the multiple myeloma program at Mount Sinai Medical Center in

en

28:36

Episode 418: Radiation Site-Specific Side Effects:...

The ONS Podcast ·

2026/06/05

"Radiation therapy is often extremely well tolerated in colorectal cancer. Technology has really changed things. But location of the tumor can affect side effects, such as radiation dermatitis. If a patient has a low-lying tumor, if it's less than six centimeters from the anal verge, the patient is likely to have some skin reaction. It's good to be proactive if that's the case," ONS member Lorraine Drapek, DNP, FNP-BC, AOCNP®, nurse practitioner in the Department of Radiation Oncology at

en

35:22

Episode 417: Pharmacology 101: Oncolytic Viral Therapy

The ONS Podcast ·

2026/05/29

"There are a lot of specifics that nurses need to keep in mind as they are administering this herpes simplex modified virus to patients because accidental exposure is of concern both to the patient, to their family members, as well as to healthcare workers. I always recommend nurses wear personal protective equipment, such as a gown, safety glasses, gloves, and/or a face shield," Heidi Finnes, PharmD, RPh, BCOP, director of clinical ambulatory practice at Mayo Clinic and assistant professor of

en

All Episodes

Similar Podcasts

Доктор Тройняшкин

Доктор Тройняшкин

Healthy Chat

DR ALI BANIHAMOUR

Dingue ‐ RTS

RTS - Radio Télévision Suisse

Raw Reality

TORISSTORY & FITWITHLILY

The Jordan Syatt Podcast

Jordan Syatt